Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 févr. 2012 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Present at the 14th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 7, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at...
02 févr. 2012 16h01 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Appointment of Dr. Adam R. Craig as Chief Medical Officer

Eric Bjerkholt Promoted to Executive Vice President, Corporate Development and Finance Steven Ketchum, Senior Vice President, Research and Development, to Transition from Executive to Board...
12 déc. 2011 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Participation in Cardiff University Sponsored Phase 2/3 Trial Evaluating Vosaroxin in Newly Diagnosed Elderly AML and High-Risk MDS Patients

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced participation in a Phase 2/3 randomized, controlled, multicenter trial...
09 déc. 2011 07h06 HE | Source: Sunesis Pharmaceuticals, Inc.

Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial Based on Periodic Safety Review

SOUTH SAN FRANCISCO, Calif., Dec. 9, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the independent Data and Safety Monitoring Board (DSMB) for the VALOR...
06 déc. 2011 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Present at the Oppenheimer 22nd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 6, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at...
14 nov. 2011 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Reports Third Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2011. Net loss for...
08 nov. 2011 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Present at the Lazard Capital Markets 8th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology...
19 oct. 2011 16h15 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Secures $25 Million Tranched Loan Facility

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has entered into a $25 million tranched loan facility. Under the...
11 oct. 2011 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis to Host Analyst & Institutional Investor Meeting on October 19, 2011

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will host an analyst and institutional investor meeting on...
26 sept. 2011 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Initiation of Phase 1 Study of MLN2480 in Advanced Solid Tumors

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the initiation of a Phase 1 clinical study of MLN2480, an oral,...

Page précédente